Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India ○
found
a story from CNBC ⚠️ › World News
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.